Emgality vs Vyepti
A side-by-side look at two neurology medications advertised on TV. Informational only — not medical advice.
| US Emgality | US Vyepti | |
|---|---|---|
| Generic name | galcanezumab | eptinezumab |
| Drug class | CGRP Antagonist (Biologic) | Anti-CGRP Monoclonal Antibody |
| Treats | Migraine prevention, cluster headache | Migraine prevention |
| Category | Neurology | Neurology |
| Manufacturer | Eli Lilly | Lundbeck |
| Year approved | 2018 | 2020 |
| FDA warning | No boxed warning | No boxed warning |
| Est. TV ad spend | $110M | — |
| Common side effects | Injection site reactions, Constipation, Itching, Allergic reactions | Stuffy nose and sore throat, Allergic reactions, Fatigue |
Frequently asked questions
Is Emgality or Vyepti better?
Neither is universally "better." Emgality (galcanezumab) and Vyepti (eptinezumab) are both used for neurology, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Emgality and Vyepti?
Emgality is a CGRP Antagonist (Biologic) made by Eli Lilly, while Vyepti is a Anti-CGRP Monoclonal Antibody made by Lundbeck. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Emgality has the larger estimated TV advertising budget of the two.